Symbols / MYNZ
MYNZ Chart
About
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 5.54M |
| Enterprise Value | 3.69M | Income | -18.97M | Sales | 659.93K |
| Book/sh | 0.62 | Cash/sh | 0.47 | Dividend Yield | — |
| Payout | 0.00% | Employees | 19 | IPO | — |
| P/E | — | Forward P/E | -0.83 | PEG | — |
| P/S | 8.40 | P/B | 0.99 | P/C | — |
| EV/EBITDA | -0.23 | EV/Sales | 5.59 | Quick Ratio | 0.35 |
| Current Ratio | 0.52 | Debt/Eq | 122.65 | LT Debt/Eq | — |
| EPS (ttm) | -5.28 | EPS next Y | -0.74 | EPS Growth | — |
| Revenue Growth | -44.90% | Earnings | 2024-04-09 06:00 | ROA | -114.35% |
| ROE | — | ROIC | — | Gross Margin | 67.50% |
| Oper. Margin | -28.22% | Profit Margin | 0.00% | Shs Outstand | 9.06M |
| Shs Float | 3.63M | Short Float | 3.58% | Short Ratio | 0.57 |
| Short Interest | — | 52W High | 6.29 | 52W Low | 0.55 |
| Beta | 0.27 | Avg Volume | 474.86K | Volume | 348.22K |
| Target Price | $14.00 | Recom | None | Prev Close | $0.59 |
| Price | $0.61 | Change | 3.45% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.00
Mean price target
2. Current target
$0.61
Latest analyst target
3. DCF / Fair value
$-16.26
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.61
Low
$14.00
High
$14.00
Mean
$14.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-02-14 | init | Maxim Group | — → Buy | $14 |
| 2024-11-25 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-04-12 | reit | Cantor Fitzgerald | — → Neutral | — |
| 2024-03-06 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2023-11-21 | down | Cantor Fitzgerald | Overweight → Neutral | — |
| 2023-11-20 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-09-26 | reit | Cantor Fitzgerald | Overweight → Overweight | $9 |
| 2023-09-22 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-09-14 | reit | Cantor Fitzgerald | Overweight → Overweight | $9 |
| 2023-08-22 | reit | Cantor Fitzgerald | Overweight → Overweight | $9 |
| 2023-08-18 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-06-01 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2023-05-18 | main | Cantor Fitzgerald | Overweight → Overweight | $12 |
| 2023-04-27 | main | HC Wainwright & Co. | — → Buy | $10 |
| 2023-03-30 | reit | HC Wainwright & Co. | — → Buy | $25 |
| 2023-02-16 | reit | HC Wainwright & Co. | — → Buy | $25 |
| 2023-02-10 | init | JonesTrading | — → Buy | $11 |
| 2022-10-25 | init | Cantor Fitzgerald | — → Overweight | $15 |
| 2022-06-21 | init | HC Wainwright & Co. | — → Buy | $25 |
- $MYNZ stock is down 12% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Feb 2026 14
- Cancer test maker secures $6M to build U.S. pancreatic screening business - Stock Titan ue, 17 Feb 2026 12
- Can Mainz Biomed Stock Hold Up When Markets Turn? - Trefis Sun, 21 Dec 2025 08
- 2 Small-Cap Biotechs That Could Reward Patient Investors - Yahoo Finance Fri, 12 Dec 2025 08
- Mainz Biomed Raises Up to $6 Million in Two-Step Preferred Stock Investment From David Lazar - TradingView ue, 17 Feb 2026 12
- Mainz Biomed Announces $6 Mln Private Placement In Two Tranches To Fund Operations, Stock Down - Nasdaq ue, 17 Feb 2026 14
- Mainz Biomed completes ATM share sales, retains capacity - TipRanks ue, 10 Feb 2026 08
- Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update - ChartMill ue, 17 Feb 2026 12
- 100% sensitivity: Mainz Biomed biomarker panel shows 95% specificity in 30‑patient pancreatic study - Stock Titan Wed, 08 Oct 2025 07
- Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges - Investing.com Mon, 19 May 2025 07
- Why MYNZ Stock is Making Waves - StocksToTrade Mon, 28 Apr 2025 07
- Insider Purchase: 10% owner at $MYNZ Buys 643,850 Shares | MYNZ Stock News - Quiver Quantitative Fri, 16 Jan 2026 08
- Mainz Biomed Secures Strategic Investment and Restructures Operations - TipRanks ue, 17 Feb 2026 13
- Mainz Biomed (NASDAQ: MYNZ) joins MEDICA 2025; ColoAlert featured amid 80,000 visitors - Stock Titan Wed, 12 Nov 2025 08
- Mainz Biomed raises $2.15 million through at-the-market share offering - Investing.com Nigeria ue, 10 Feb 2026 23
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -19.31M | -24.92M | -25.72M | -9.26M |
| TotalUnusualItems | -248.83K | 48.68K | 0.00 | -2.02M |
| TotalUnusualItemsExcludingGoodwill | -248.83K | 48.68K | 0.00 | -2.02M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -21.65M | -26.30M | -26.39M | -11.69M |
| ReconciledDepreciation | 1.02M | 866.41K | 379.80K | 69.93K |
| ReconciledCostOfRevenue | 319.11K | 385.82K | 123.17K | 368.18K |
| EBITDA | -19.56M | -24.87M | -25.72M | -11.28M |
| EBIT | -20.58M | -25.74M | -26.10M | -11.35M |
| NetInterestIncome | -1.08M | -809.58K | -289.32K | -339.17K |
| InterestExpense | 1.08M | 559.58K | 289.32K | 339.17K |
| NormalizedIncome | -21.40M | -26.34M | -26.39M | -9.67M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -21.65M | -26.30M | -26.39M | -11.69M |
| TotalExpenses | 19.31M | 27.54M | 26.97M | 10.30M |
| TotalOperatingIncomeAsReported | -18.70M | -26.64M | -26.44M | -9.72M |
| DilutedAverageShares | 968.23K | 406.06K | 353.94K | 180.27K |
| BasicAverageShares | 968.23K | 406.06K | 353.94K | 180.27K |
| DilutedEPS | -22.36 | -64.76 | -74.55 | -64.80 |
| BasicEPS | -22.36 | -64.76 | -74.55 | -64.80 |
| DilutedNIAvailtoComStockholders | -21.65M | -26.30M | -26.39M | -11.69M |
| NetIncomeCommonStockholders | -21.65M | -26.30M | -26.39M | -11.69M |
| NetIncome | -21.65M | -26.30M | -26.39M | -11.69M |
| NetIncomeIncludingNoncontrollingInterests | -21.65M | -26.30M | -26.39M | -11.69M |
| NetIncomeContinuousOperations | -21.65M | -26.30M | -26.39M | -11.69M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -21.65M | -26.30M | -26.39M | -11.69M |
| OtherIncomeExpense | -2.16M | 1.16M | 346.03K | -1.63M |
| OtherNonOperatingIncomeExpenses | -1.91M | 1.11M | 346.03K | 393.42K |
| SpecialIncomeCharges | -248.83K | 48.68K | 0.00 | -2.02M |
| GainOnSaleOfBusiness | 28.33K | 0.00 | 0.00 | |
| OtherSpecialCharges | -48.68K | |||
| WriteOff | 47.45K | 0.00 | 0.00 | 0.00 |
| RestructuringAndMergernAcquisition | 229.71K | 0.00 | 0.00 | 2.02M |
| NetNonOperatingInterestIncomeExpense | -1.08M | -809.58K | -289.32K | -339.17K |
| TotalOtherFinanceCost | 250.00K | 139.97K | ||
| InterestExpenseNonOperating | 1.08M | 559.58K | 289.32K | 339.17K |
| OperatingIncome | -18.42M | -26.64M | -26.44M | -9.72M |
| OperatingExpense | 18.99M | 27.15M | 26.63M | 9.90M |
| OtherOperatingExpenses | -269.29K | -350.41K | ||
| DepreciationAmortizationDepletionIncomeStatement | 379.18K | 342.40K | 155.24K | 38.38K |
| DepreciationAndAmortizationInIncomeStatement | 379.18K | 342.40K | 155.24K | 38.38K |
| DepreciationIncomeStatement | 29.52K | |||
| ResearchAndDevelopment | 5.84M | 9.59M | 5.02M | 481.93K |
| SellingGeneralAndAdministration | 12.77M | 17.22M | 21.45M | 9.38M |
| SellingAndMarketingExpense | 4.70M | 3.80M | 5.02M | 626.37K |
| GeneralAndAdministrativeExpense | 8.08M | 13.42M | 16.43M | 8.76M |
| OtherGandA | 3.89M | 5.58M | 3.82M | 1.25M |
| InsuranceAndClaims | 536.55K | 817.18K | 920.12K | 170.46K |
| SalariesAndWages | 3.65M | 7.02M | 11.69M | 7.33M |
| GrossProfit | 574.88K | 509.66K | 182.15K | 177.62K |
| CostOfRevenue | 319.11K | 385.82K | 347.73K | 399.73K |
| TotalRevenue | 893.99K | 895.48K | 529.88K | 577.35K |
| OperatingRevenue | 893.99K | 895.48K | 529.88K | 577.35K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 2.32M | 529.14K | 365.74K | 300.25K |
| ShareIssued | 2.32M | 529.14K | 365.74K | 300.25K |
| TotalDebt | 3.27M | 7.42M | 3.23M | 2.58M |
| TangibleBookValue | 3.03M | -145.42K | 14.10M | 6.36M |
| InvestedCapital | 8.17M | 9.22M | 16.08M | 8.49M |
| WorkingCapital | 1.89M | -257.04K | 14.14M | 8.26M |
| NetTangibleAssets | 3.03M | -145.42K | 14.10M | 6.36M |
| CapitalLeaseObligations | 1.15M | 1.45M | 1.24M | 442.84K |
| CommonStockEquity | 6.05M | 3.25M | 14.10M | 6.36M |
| TotalCapitalization | 6.05M | 4.28M | 15.04M | 8.30M |
| TotalEquityGrossMinorityInterest | 6.05M | 3.25M | 14.10M | 6.36M |
| StockholdersEquity | 6.05M | 3.25M | 14.10M | 6.36M |
| GainsLossesNotAffectingRetainedEarnings | 27.04M | 20.83M | 18.13M | 9.74M |
| OtherEquityAdjustments | 27.04M | 20.83M | 18.13M | 9.74M |
| RetainedEarnings | -90.98M | -69.33M | -43.03M | -16.64M |
| AdditionalPaidInCapital | 69.07M | 51.51M | 38.83M | 13.13M |
| CapitalStock | 922.12K | 235.82K | 164.90K | 141.07K |
| CommonStock | 922.12K | 235.82K | 164.90K | 141.07K |
| TotalLiabilitiesNetMinorityInterest | 7.19M | 12.16M | 6.14M | 3.68M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.24M | 2.92M | 1.90M | 2.33M |
| OtherNonCurrentLiabilities | 376.10K | 726.98K | ||
| DerivativeProductLiabilities | 1.94M | |||
| LongTermDebtAndCapitalLeaseObligation | 865.98K | 2.20M | 1.90M | 2.33M |
| LongTermCapitalLeaseObligation | 865.98K | 1.17M | 959.12K | 387.77K |
| LongTermDebt | 1.03M | 943.21K | 1.94M | |
| CurrentLiabilities | 5.95M | 9.24M | 4.24M | 1.35M |
| OtherCurrentLiabilities | 690.58K | 388.84K | ||
| CurrentDeferredLiabilities | 0.00 | 138.89K | 199.41K | |
| CurrentDeferredRevenue | 0.00 | 138.89K | 199.41K | |
| CurrentDebtAndCapitalLeaseObligation | 2.41M | 5.22M | 1.33M | 248.51K |
| CurrentCapitalLeaseObligation | 280.14K | 288.46K | 285.35K | 55.08K |
| CurrentDebt | 2.13M | 4.94M | 1.04M | 193.43K |
| OtherCurrentBorrowings | 2.13M | 4.94M | 1.04M | 193.43K |
| PayablesAndAccruedExpenses | 2.85M | 3.48M | 2.72M | 1.10M |
| CurrentAccruedExpenses | 1.04M | 857.94K | 1.38M | 267.51K |
| Payables | 1.81M | 2.63M | 1.33M | 835.74K |
| OtherPayable | 233.71K | |||
| DuetoRelatedPartiesCurrent | 558.51K | 299.94K | ||
| TotalTaxPayable | 0.00 | 3.22K | ||
| AccountsPayable | 1.25M | 2.33M | 1.33M | 832.52K |
| TotalAssets | 13.24M | 15.41M | 20.24M | 10.04M |
| TotalNonCurrentAssets | 5.39M | 6.43M | 1.86M | 431.59K |
| OtherNonCurrentAssets | 108.00 | 23.27K | ||
| GoodwillAndOtherIntangibleAssets | 3.02M | 3.39M | 0.00 | 0.00 |
| NetPPE | 2.38M | 3.03M | 1.84M | 431.59K |
| AccumulatedDepreciation | -1.35M | -895.10K | -472.54K | -218.78K |
| GrossPPE | 3.72M | 3.93M | 2.31M | 650.36K |
| Leases | 489.14K | |||
| ConstructionInProgress | 0.00 | 59.93K | 0.00 | |
| OtherProperties | 1.51M | 1.59M | 942.14K | 100.77K |
| MachineryFurnitureEquipment | 612.38K | 616.22K | 334.58K | 60.45K |
| BuildingsAndImprovements | 1.60M | 1.66M | 1.04M | 489.14K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 7.84M | 8.98M | 18.38M | 9.61M |
| OtherCurrentAssets | 108.00 | |||
| PrepaidAssets | 1.02M | 940.72K | 801.96K | 769.83K |
| Inventory | 372.87K | 613.64K | 175.47K | 0.00 |
| InventoriesAdjustmentsAllowances | -25.06K | -56.83K | 0.00 | |
| FinishedGoods | 84.25K | 240.47K | 0.00 | |
| RawMaterials | 313.68K | 430.00K | 175.47K | |
| Receivables | 213.75K | 354.51K | 259.14K | 111.84K |
| OtherReceivables | 3.25K | 558.00 | ||
| DuefromRelatedPartiesCurrent | 17.24K | 0.00 | ||
| TaxesReceivable | 162.93K | 260.95K | 192.15K | 94.08K |
| AccountsReceivable | 33.58K | 93.56K | 63.74K | 17.20K |
| AllowanceForDoubtfulAccountsReceivable | 0.00 | -28.18K | -66.85K | -796.00 |
| GrossAccountsReceivable | 33.58K | 121.73K | 130.59K | 18.00K |
| CashCashEquivalentsAndShortTermInvestments | 6.24M | 7.07M | 17.14M | 8.73M |
| CashAndCashEquivalents | 6.24M | 7.07M | 17.14M | 8.73M |
| CashFinancial | 6.24M | 7.07M | 17.14M | 8.73M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -17.34M | -23.84M | -15.43M | -3.24M |
| RepaymentOfDebt | -1.48M | -2.29M | -304.97K | -61.24K |
| IssuanceOfDebt | 4.31M | 10.12M | 0.00 | 246.61K |
| IssuanceOfCapitalStock | 13.76M | 6.39M | 23.87M | 10.43M |
| CapitalExpenditure | -254.95K | -1.90M | -658.48K | -16.70K |
| InterestPaidSupplementalData | 198.06K | 153.58K | 125.54K | 46.24K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | |
| EndCashPosition | 6.24M | 7.07M | 17.14M | 8.73M |
| BeginningCashPosition | 7.07M | 17.14M | 8.73M | 122.57K |
| EffectOfExchangeRateChanges | -146.06K | -459.86K | -101.11K | 11.61K |
| ChangesInCash | -689.20K | -9.61M | 8.52M | 8.59M |
| FinancingCashFlow | 16.60M | 14.23M | 23.94M | 10.61M |
| CashFlowFromContinuingFinancingActivities | 16.60M | 14.23M | 23.94M | 10.61M |
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | 382.50K | 0.00 |
| NetCommonStockIssuance | 13.76M | 6.39M | 23.87M | 10.43M |
| CommonStockIssuance | 13.76M | 6.39M | 23.87M | 10.43M |
| NetIssuancePaymentsOfDebt | 2.83M | 7.83M | -304.97K | 185.37K |
| NetShortTermDebtIssuance | 3.13M | 9.02M | 0.00 | 7.67K |
| ShortTermDebtPayments | -1.18M | -1.10M | 0.00 | 0.00 |
| ShortTermDebtIssuance | 4.31M | 10.12M | 0.00 | 7.67K |
| NetLongTermDebtIssuance | -295.25K | -1.19M | -304.97K | 177.70K |
| LongTermDebtPayments | -295.25K | -1.19M | -304.97K | -61.24K |
| LongTermDebtIssuance | 0.00 | 0.00 | 238.94K | |
| InvestingCashFlow | -198.82K | -1.90M | -658.48K | 1.20M |
| CashFlowFromContinuingInvestingActivities | -198.82K | -1.90M | -658.48K | 1.20M |
| NetBusinessPurchaseAndSale | 32.78K | 0.00 | 0.00 | 1.22M |
| SaleOfBusiness | 32.78K | 0.00 | 0.00 | 1.22M |
| NetIntangiblesPurchaseAndSale | -150.00K | -700.00K | 0.00 | |
| PurchaseOfIntangibles | -150.00K | -700.00K | 0.00 | |
| NetPPEPurchaseAndSale | -81.60K | -1.20M | -658.48K | -16.70K |
| SaleOfPPE | 23.35K | 0.00 | 0.00 | |
| PurchaseOfPPE | -104.95K | -1.20M | -658.48K | -16.70K |
| OperatingCashFlow | -17.09M | -21.94M | -14.77M | -3.22M |
| CashFlowFromContinuingOperatingActivities | -17.09M | -21.94M | -14.77M | -3.22M |
| ChangeInWorkingCapital | 51.75K | -64.63K | 1.39M | -138.62K |
| ChangeInOtherWorkingCapital | -135.72K | -60.52K | 173.90K | 11.08K |
| ChangeInPayablesAndAccruedExpense | 84.61K | 720.24K | 1.65M | 659.64K |
| ChangeInPrepaidAssets | 8.77K | -239.70K | -53.79K | -833.56K |
| ChangeInInventory | 29.81K | -500.19K | -172.38K | 0.00 |
| ChangeInReceivables | 64.28K | 15.54K | -211.23K | 24.21K |
| ChangesInAccountReceivables | 24.21K | |||
| OtherNonCashItems | 156.72K | 168.11K | -38.60K | 2.11M |
| StockBasedCompensation | 1.14M | 4.01M | 9.82M | 6.43M |
| UnrealizedGainLossOnInvestmentSecurities | 2.05M | -661.00K | 0.00 | 0.00 |
| AssetImpairmentCharge | 221.87K | 91.04K | 65.39K | 0.00 |
| DepreciationAmortizationDepletion | 1.02M | 866.41K | 379.80K | 69.93K |
| DepreciationAndAmortization | 1.02M | 866.41K | 379.80K | 69.93K |
| OperatingGainsLosses | -75.15K | -48.68K | ||
| GainLossOnSaleOfPPE | -46.82K | 0.00 | 0.00 | |
| GainLossOnSaleOfBusiness | -28.33K | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | -21.65M | -26.30M | -26.39M | -11.69M |
Public Trades for MYNZ
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|